货号:GS40612
Risankizumab is a humanized monoclonal antibody targeting interleukin-23 (IL-23). It binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor and downstream signaling. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物